We are pioneers of a new medical subspecialty as an answer to the opioid epidemic.
We are board-certified physicians specializing in the treatment of opiate use disorder.
We are uniquely qualified to help physicians navigate the serious consequences that can come from prescribing opiates.
We are BlueDoor Therapeutics.
Ravi Chandiramani, ND - Medical Director
Dr. Chandiramani graduated from Bastyr University with a doctorate in naturopathic medicine. He is a pioneer in the field of integrative addiction medicine (I-AM) … READ MORE »
Frank Lovecchio, DO, MPH, FACEP - Medical Director
Dr. Lovecchio has studied and treated patients with drug use issues for over two decades and has served as the Medical Director of the Poison Control Center… READ MORE »
Gina Mecagni Berman, MD - Chief Executive Officer
Dr. Berman graduated from Georgetown University with her doctorate of medicine and is board certified in addiction and emergency medicine … READ MORE »
The CDC will tell you why to get your patients off opiates. BlueDoor knows how to.
Physicians aren’t typically trained to manage opioid endocrinopathy or withdrawals.
Each medical specialty should send their opiate dependent patients to a physician experienced in addiction medicine.
Are you prepared to handle the consequences that come with prescribing opiates? Are you aware that the risk of becoming dependent on opioids is higher among patients with sleep apnea or other causes of sleep-disordered breathing, patients with renal or hepatic insufficiency, older adults, pregnant women, patients with depression or other mental health conditions, and patients with alcohol or other substance use disorders?
The time has come for physicians to stop practicing medicine where they lack training. Patients are dying in record numbers from the first medically-derived epidemic in history – more than 165,000 people from 1999-2014.
Just as an Internist sends their patients with fractures to an Orthopedist, each specialty should send their opiate dependent patients to a physician fully versed in addiction medicine.
Are you qualified to manage your patients’ withdrawal? If not, make your next prescription for Blue Door Therapeutics.
These CDC guidelines help with the why of prescribing opiates:
- Opioids are not first-line or routine therapy for chronic pain
- Establish and measure goals for pain and function
- Discuss benefits and risks and availability of nonopioid therapies with patient
- Use immediate-release opioids when starting
- Start low and go slow
- When opioids are needed for acute pain, prescribe no more than needed
- Do not prescribe ER/LA opioids for acute pain
- Follow-up and re-evaluate risk of harm; reduce dose or taper and discontinue if needed
- Evaluate risk factors for opioid-related harms
- Check PDMP for high dosages and prescriptions from other providers
- Use urine drug testing to identify prescribed substances and undisclosed use
- Avoid concurrent benzodiazepine and opioid prescribing
- Arrange treatment for opioid use disorder if needed
But, where do you go to find out how to get patients off opiates? Finally, you have an answer to that question and a partner to work with – BlueDoor Therapeutics.
Are your patients asking about medical cannabis as an alternative to their chronic pain treatment? BlueDoor has extensive experience in cannabis supported treatment, and is a pioneer in the field.
Our combined experience and expertise make the BlueDoor team uniquely qualified to help manage your opiate dependent patients. Together, we can take on the opioid epidemic, avoid patient suffering and death, and embrace a holistic approach to pain management. It all starts with a phone call.